NeoGenomics, Inc. (NASDAQ:NEO – Get Rating) has been assigned a consensus rating of “Moderate Buy” from the fourteen research firms that are presently covering the stock, MarketBeat.com reports. Five research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. The average 1 year price target among brokers that have covered the stock in the last year is $18.55.
NEO has been the topic of several research analyst reports. StockNews.com raised NeoGenomics from a “sell” rating to a “hold” rating in a research report on Saturday, February 25th. Cowen raised their target price on NeoGenomics from $14.00 to $20.00 and gave the stock an “outperform” rating in a research report on Friday, February 24th. Benchmark raised NeoGenomics from a “hold” rating to a “buy” rating and set a $20.00 target price on the stock in a research report on Friday, February 24th. Raymond James raised their target price on NeoGenomics from $12.00 to $19.00 and gave the stock an “outperform” rating in a research report on Friday, February 24th. Finally, Piper Sandler raised their target price on NeoGenomics from $18.00 to $20.00 and gave the stock an “overweight” rating in a research report on Friday, March 3rd.
Institutional Trading of NeoGenomics
A number of institutional investors have recently modified their holdings of NEO. Quadrant Capital Group LLC raised its holdings in shares of NeoGenomics by 149.5% in the third quarter. Quadrant Capital Group LLC now owns 3,027 shares of the medical research company’s stock worth $26,000 after acquiring an additional 1,814 shares during the last quarter. Ronald Blue Trust Inc. purchased a new stake in shares of NeoGenomics in the second quarter worth about $28,000. CWM LLC boosted its holdings in NeoGenomics by 115.8% in the fourth quarter. CWM LLC now owns 3,924 shares of the medical research company’s stock valued at $36,000 after purchasing an additional 2,106 shares during the last quarter. Security Benefit Life Insurance Co. KS purchased a new position in NeoGenomics in the second quarter valued at about $44,000. Finally, Captrust Financial Advisors lifted its holdings in NeoGenomics by 17.1% during the 2nd quarter. Captrust Financial Advisors now owns 5,780 shares of the medical research company’s stock worth $47,000 after buying an additional 844 shares during the last quarter. 88.15% of the stock is currently owned by hedge funds and other institutional investors.
NeoGenomics Stock Performance
NeoGenomics Company Profile
NeoGenomics, Inc is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups.
- Get a free copy of the StockNews.com research report on NeoGenomics (NEO)
- Meta Platforms: Efficiency Gains Momentum, Stock Accelerates
- Pfizer’s Latest Acquisition Strengthens the Case for PFE Stock
- SentinelOne: Reversal In-Play For Cybersecurity Stocks
- Is Sportradar Group A Growth Stock To Bet On In 2023?
- Strong Guidance says Boeing is Ready for Takeoff
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.